Coadministration of scopolamine and mGlu2 NAM VU6001966 as a novel antidepressant approach: Lowering effective dose and reducing cognitive side effects
Coadministration of scopolamine with the mGlu2 NAM VU6001966 may offer a promising therapeutic strategy for the treatment of depression. Further studies are needed to clarify the underlying mechanisms and confirm its efficacy.
Authors
- Bartosz Bobula (ORCID: https://orcid.org/0000-0001-5167-9277)
- Piotr Brański (ORCID: https://orcid.org/0000-0001-6126-0269)
- Agnieszka Pałucha-Poniewiera (ORCID: https://orcid.org/0000-0001-9890-6844)
- Dorota Bederska‐Łojewska (ORCID: https://orcid.org/0000-0002-9958-3730)
- Andrzej Pilc (ORCID: https://orcid.org/0000-0002-4045-0597)
- Yana Babii (ORCID: https://orcid.org/0000-0001-7282-1236)
- Agnieszka Kania
Institutions
- Maj Institute of Pharmacology (PL)
- Polish Academy of Sciences (PL)
Publication Details
- Journal
- Psychopharmacology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1007/s00213-025-06916-6
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Narodowym Centrum Nauki
- Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk